Nestlé Health Science has signed an exclusive agreement outside of the United States and Canada to support the potential future commercialisation of Seres Therapeutics' novel ‘microbiome therapeutics’.
The aim is to treat Inflammatory Bowel Disease (IBD) and Clostridium difficile (C.diff), an intestinal infection caused by the C.diff bacteria that can be life-threatening in some cases.
Nestlé Health Science will invest CHF 121 million (USD 120 million) upfront to support Seres’ ‘Ecobiotics’, a new class of biological drugs based upon microbial organisms. These target the microbiome – the 100 trillion microorganisms that live in the body.
Scientific research increasingly links an unhealthy or unbalanced microbiome to a range of health conditions, including IBD and C.diff.
Read the full press release on the Nestlé Health Science website.